NUVL250117C155000
- 0.00
- 0.000.00%
Nuvalent Newsroom
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
H.C. Wainwright Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $110
Express News | Nuvalent, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $110
Jefferies Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $137
Nuvalent Insider Sold Shares Worth $2,338,436, According to a Recent SEC Filing
Nuvalent Elects Grant Bogle as Independent Director
Express News | Nuvalent Appoints Grant Bogle to Board of Directors
Barclays Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
J.P. Morgan Reaffirms Their Buy Rating on Nuvalent (NUVL)
Express News | Nuvalent Inc : JP Morgan Cuts Target Price to $121 From $125
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Nuvalent's Promising ALK and ROS1 Programs Drive Buy Rating Amid Strong Financial Position and Upcoming Trials
BMO Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $134
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $132
TD Cowen Maintains Nuvalent(NUVL.US) With Buy Rating
Nuvalent Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Outperform on Nuvalent, Raises Price Target to $134
Nuvalent Analyst Ratings